News | Ventricular Assist Devices (VAD) | October 05, 2015

Catheter-Based Heart Failure Pump Wins Innovative Technology Design Competition

Six-cm device features powerful micro-pump to rest and heal the heart without surgery
 

Procyrion, Aortix device, grand prize, Create the Future Design Contest

October 5, 2015 — Procyrion Inc. of Houston has been awarded the grand prize of $20,000 in the 2015 "Create the Future" Design Contest for the first catheter-deployed heart pump intended for long-term treatment of chronic heart failure. The Aortix device — thinner than a No. 2 pencil and only 6 cm long — features a powerful micro-pump designed to rest and heal the heart without surgery and with minimal risk.

Aortix was among the record 1,159 new product ideas submitted in the 13th annual design contest, which was established in 2002 to recognize and reward engineering innovations that benefit humanity, the environment and the economy. This year's design contest was co-sponsored by COMSOL and Mouser Electronics. Analog Devices and Intel were supporting sponsors.

In addition to the grand prize of $20,000, first-place winners were named in seven categories in various industries. In the medical field Smart X-ray Source won for combining flat panel X-ray detector technology with classic X-ray physics to provide portable, inexpensive computed tomography (CT) systems using open software sources to underserved populations around the world.

Finalists were selected by senior editors at Tech Briefs Media Group and judged by an independent panel of design engineers. Visitors to the contest website could vote on entries, with the 10 most popular designs awarded an Ollie robotic gaming device provided by Sphero.

For more information: www.createthefuturecontest.com


Related Content

News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart ...

Home September 19, 2024
Home
Subscribe Now